首页> 美国卫生研究院文献>International Journal of Nanomedicine >Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on hepatocyte-targeting efficiency in vitro and in vivo
【2h】

Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on hepatocyte-targeting efficiency in vitro and in vivo

机译:新型四价半乳糖基化DTPA-DSPE的合成及体内外肝细胞靶向效率的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

For the purposes of obtaining a hepatocyte-selective drug delivery system, a novel tetravalent galactosylated diethylenetriaminepentaacetic acid-distearoyl phosphatidylethanolamine (4Gal-DTPA-DSPE) was synthesized. The chemical structure of 4Gal-DTPA-DSPE was confirmed by proton nuclear magnetic resonance and mass spectrometry. The four galactose-modified liposomes (4Gal-liposomes) were prepared by thin-film hydration method, then doxorubicin (DOX) was encapsulated into liposomes using an ammonium sulfate gradient loading method. The liposomal formulations with 4Gal-DTPA-DSPE were characterized by laser confocal scanning microscopy and flow cytometry analysis, and the results demonstrated that the 4Gal-liposomes facilitated the intracellular uptake of DOX into HepG2 cells via asialoglycoprotein receptor-mediated endocytosis. Cytotoxicity assay showed that the cell proliferation inhibition effect of 4Gal-liposomes was higher than that of the conventional liposomes without the galactose. Additionally, pharmacokinetic experiments in rats revealed that the 4Gal-liposomes displayed slower clearance from the systemic circulation compared with conventional liposomes. The organ distributions in mice and the study on frozen sections of liver implied that the 4Gal-liposomes enhanced the intracellular uptake of DOX into hepatocytes and prolonged the circulation. Taken together, these results indicate that liposomes containing 4Gal-DTPA-DSPE have great potential as drug delivery carriers for hepatocyte-selective targeting.
机译:为了获得肝细胞选择性药物递送系统,合成了新型的四价半乳糖基化的二亚乙基三胺五乙酸-二硬脂酰磷脂酰乙醇胺(4Gal-DTPA-DSPE)。通过质子核磁共振和质谱证实了4Gal-DTPA-DSPE的化学结构。通过薄膜水化法制备四个半乳糖修饰脂质体(4Gal-脂质体),然后用硫酸铵梯度加载法将阿霉素(DOX)包裹入脂质体中。通过激光共聚焦显微镜和流式细胞术分析表征了具有4Gal-DTPA-DSPE的脂质体制剂,结果表明4Gal-脂质体通过脱唾液酸糖蛋白受体介导的内吞作用促进了DOX进入HepG2细胞的细胞内摄取。细胞毒性试验表明,4Gal-脂质体的细胞增殖抑制作用高于不加半乳糖的常规脂质体。另外,在大鼠中的药代动力学实验表明,与常规脂质体相比,4Gal脂质体显示出较慢的从全身循环中清除的能力。小鼠的器官分布和对肝脏冰冻切片的研究表明,4Gal脂质体增强了DOX对肝细胞的细胞内摄取并延长了循环。综上所述,这些结果表明,含有4Gal-DTPA-DSPE的脂质体具有作为肝细胞选择性靶向药物递送载体的巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号